NCT05143528View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,275

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 1, 2026

Conditions
Alzheimer Disease
Interventions
DRUG

Nilotinib BE 84mg

84 mg capsule

DRUG

Nilotinib BE 112 mg

112 mg capsule

DRUG

Placebo

placebo capsule

Sponsors

Lead Sponsor

KeifeRx, LLC
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

collaborator

Life Molecular Imaging GmbH

INDUSTRY

collaborator

Sun Pharmaceuticals Industries Limited

UNKNOWN

lead

KeifeRx, LLC

INDUSTRY